Eli Lilly (LLY)
(Real Time Quote from BATS)
$886.47 USD
+0.92 (0.10%)
Updated Oct 4, 2024 03:55 PM ET
After-Market: $885.55 -0.92 (-0.10%) 4:18 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$886.47 USD
+0.92 (0.10%)
Updated Oct 4, 2024 03:55 PM ET
After-Market: $885.55 -0.92 (-0.10%) 4:18 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
Zacks News
State of California Sues Insulin Makers for Unfair Practices
by Zacks Equity Research
The lawsuit aims to curb the skyrocketing cost of insulin charged by insulin manufacturers and pharmacy benefit managers companies. The State also seeks to recover some monetary compensation.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $359.12 in the latest trading session, marking a -0.36% move from the prior day.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe
by Zacks Equity Research
Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early Alzheimer's disease in Europe.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Campbell Soup and Eli Lilly have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Campbell Soup and Eli Lilly have been highlighted as Zacks Bull and Bear of the Day.
Bear of the Day: Eli Lilly (LLY)
by Kevin Cook
Guidance for this year drags down analyst EPS estimates by nearly 10% to just 9% growth
Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's
by Zacks Equity Research
FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $362.94 in the latest trading session, marking a +1.12% move from the prior day.
Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Lilly (LLY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Eli Lilly (LLY) Stock Moves -0.23%: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $364.99, marking a -0.23% move from the previous day.
SNY or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SNY vs. LLY: Which Stock Is the Better Value Option?
Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More
by Zacks Equity Research
Updates from Gilead Sciences (GILD) and ProQR (PRQR) are the key highlights from the biotech sector during the past week.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $365.22, marking a +0.09% move from the previous day.
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $364.88, marking a -0.82% move from the previous day.
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly
by Zacks Equity Research
ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.
The Zacks Analyst Blog Highlights United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly
by Zacks Equity Research
United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly are part of the Zacks top Analyst Blog.
Roche (RHHBY) Actemra Gets FDA Nod for Adults With COVID-19
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for Actemra (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalized adult patients. The drug was earlier granted an EUA.
3 Drug Stocks Most Wall Street Analysts Are Bullish About
by Ekta Bagri
Here we present three drug and biotech stocks, UTHR, ITCI and IMCR, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.
Wall Street Analysts Think Lilly (LLY) Is a Good Investment: Is It?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Lilly (LLY) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Eli Lilly (LLY) Stock Moves -0.58%: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $357.78, marking a -0.58% move from the previous day.
Time to Buy Eli Lilly (LLY) and AbbVie (ABBV) Stock for 2023?
by Shaun Pruitt
AbbVie's valuation, in particular, makes it a potentially strong candidate for 2023, while Eli Lilly's growth could support its stock next year.
Pharma Stock Roundup: LLY's 2023 View, MRK-MRNA Joint Cancer Vaccine Data & More
by Kinjel Shah
Eli Lilly (LLY) gives its financial guidance for 2023. Merck (MRK) and Moderna's (MRNA) mRNA-based cancer vaccine shows positive results in a joint study.
SNY vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNY vs. LLY: Which Stock Is the Better Value Option?